U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249346) titled 'Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation' on Nov. 18.
Brief Summary: This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
Study Start Date: Dec. 01
Study Type: INTERVENTIONAL
Condition:
Leukemia
Myelodysplasia
Chronic Myelomonocyt...